179 related articles for article (PubMed ID: 15879788)
1. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
Scholz M; Jennrich R; Strum S; Brosman S; Johnson H; Lam R
J Urol; 2005 Jun; 173(6):1947-52. PubMed ID: 15879788
[TBL] [Abstract][Full Text] [Related]
2. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
Nakabayashi M; Xie W; Regan MM; Jackman DM; Kantoff PW; Oh WK
Cancer; 2006 Sep; 107(5):975-81. PubMed ID: 16862573
[TBL] [Abstract][Full Text] [Related]
3. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
[TBL] [Abstract][Full Text] [Related]
6. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
7. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
Figg WD; Liu Y; Arlen P; Gulley J; Steinberg SM; Liewehr DJ; Cox MC; Zhai S; Cremers S; Parr A; Yang X; Chen CC; Jones E; Dahut WL
J Urol; 2005 Mar; 173(3):790-6. PubMed ID: 15711271
[TBL] [Abstract][Full Text] [Related]
8. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
9. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
10. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
Small EJ; Halabi S; Dawson NA; Stadler WM; Rini BI; Picus J; Gable P; Torti FM; Kaplan E; Vogelzang NJ
J Clin Oncol; 2004 Mar; 22(6):1025-33. PubMed ID: 15020604
[TBL] [Abstract][Full Text] [Related]
11. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
12. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
Pether M; Goldenberg SL; Bhagirath K; Gleave M
Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
14. Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma.
Shulman MJ; Benaim EA
Cancer; 2005 Jun; 103(11):2280-6. PubMed ID: 15844202
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
Eklund J; Kozloff M; Vlamakis J; Starr A; Mariott M; Gallot L; Jovanovic B; Schilder L; Robin E; Pins M; Bergan RC
Cancer; 2006 Jun; 106(11):2459-65. PubMed ID: 16615097
[TBL] [Abstract][Full Text] [Related]
16. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
Ryan CJ; Halabi S; Ou SS; Vogelzang NJ; Kantoff P; Small EJ
Clin Cancer Res; 2007 Apr; 13(7):2030-7. PubMed ID: 17404083
[TBL] [Abstract][Full Text] [Related]
17. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.
Svatek R; Karakiewicz PI; Shulman M; Karam J; Perrotte P; Benaim E
Eur Urol; 2006 Apr; 49(4):666-74. PubMed ID: 16423446
[TBL] [Abstract][Full Text] [Related]
18. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
[TBL] [Abstract][Full Text] [Related]
19. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
